Tirzepatide for PCOS (2026)
Quick answer: Tirzepatide (Zepbound/Mounjaro) is FDA-approved for chronic weight management and type 2 diabetes — not for PCOS. Off-label use in PCOS is growing because insulin resistance and excess weight are central to the metabolic phenotype, but PCOS-specific trial data remain limited.
Tirzepatide in PCOS care
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA for chronic weight management (as Zepbound) and type 2 diabetes (as Mounjaro). PCOS is not an approved indication, so any PCOS use is off-label — worth knowing because it affects insurance coverage and the strength of the evidence behind the prescription.
The rationale for off-label use is mechanistic: insulin resistance and excess weight drive much of the PCOS metabolic phenotype, and meaningful weight loss frequently improves cycle regularity, androgen-related symptoms, and metabolic markers. What is missing is a body of PCOS-specific randomized trials for tirzepatide itself — the improvements are inferred from its weight and glycemic effects rather than demonstrated in PCOS cohorts.
Practical notes: weight loss can restore ovulation unexpectedly, so reliable contraception matters for anyone not planning pregnancy; these medications should be stopped before conception; and gastrointestinal side effects during titration are the most common reason for discontinuation.